{"entity":{"id":"b2m","kind":"target","name":"B2M","aka":["beta-2-microglobulin","Beta-2-microglobulin"],"tldr":"B2M (Beta-2-microglobulin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Colorectal cancer, Lung cancer and 5 more.","summary":"Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation.\n\nCIViC holds 7 clinical evidence items and 0 assertions across 4 variants, naming Pembrolizumab, Nivolumab, Anti-PD-L1 Monoclonal Antibody and Immune Checkpoint Inhibitor and others. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.61, genetic association 0.00, somatic mutation 0.88). IntOGen calls it a driver in 10 cohorts (4 activating, 6 loss-of-function), covering Cervical Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Head and Neck Squamous Cell Carcinoma, Melanoma, Malignant Lymphoma, Non-Hodgkin Lymphoma and others.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:914","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:914"},{"label":"UniProt P61769","url":"https://www.uniprot.org/uniprotkb/P61769/entry"},{"label":"NCBI Gene 567","url":"https://www.ncbi.nlm.nih.gov/gene/567"},{"label":"Ensembl ENSG00000166710","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166710"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["non-hodgkin-lymphoma","colorectal","lung-cancer","head-and-neck","cervical","dlbcl","melanoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["antigen-presentation-immunoediting"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 5 therapies; IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 6 cohorts; CIViC holds 7 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"B2M","role":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:914","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:914","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P61769","url":"https://www.uniprot.org/uniprotkb/P61769/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene B2M","url":"https://civicdb.org/features/537","note":"7 evidence items, 0 assertions, 4 variants; diseases: Colorectal Cancer, Melanoma, Lung Cancer, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma and 1 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000166710","url":"https://platform.opentargets.org/target/ENSG00000166710/associations","note":"association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: colorectal cancer 0.56, melanoma 0.57, diffuse large B-cell lymphoma 0.67, non-Hodgkin lymphoma 0.72 (GraphQL API, CC0)"},{"label":"IntOGen B2M","url":"https://www.intogen.org/search?gene=B2M","note":"driver in 10 cohorts (Act 4, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:914","ensembl":"ENSG00000166710","uniprot":"P61769","entrez":"567","biology":"Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system. Exogenously applied M.tuberculosis EsxA or EsxA-EsxB (or EsxA expressed in host) binds B2M and decreases its export to the cell surface (total protein levels do not change), probably leading to defects in class I antigen presentation. Location: Secreted; Cell surface (UniProt). Locus 15q21.1 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.72 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)","Colorectal cancer: Open Targets association 0.56 with colorectal cancer (MONDO_0005575); CIViC evidence names this disease","Lung cancer: CIViC evidence names this disease","Head and neck squamous cell carcinoma: IntOGen driver in 2 cohorts (HNSC)","Cervical cancer: IntOGen driver in 1 cohort (CESC)","Diffuse large B-cell lymphoma: Open Targets association 0.67 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/b2m/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}]}}